PHEBRA has welcomed the
Government’s decision to approve
Naproxen Suspension for
reimbursement through the
Pharmaceutical Benefits Scheme,
saying it is particularly important
given its relation to pain relief for
younger patients.
Naproxen Suspension is
manufactured in Australia for
patients who cannot take a solid
dose form of a non-steroidal antiinflammatory
agent, and is
indicated for the treatment of
rheumatoid arthritis, osteoarthritis,
ankylosing spondylitis; for the
symptomatic treatment of primary
dysmenorrhoea; for the relief of
acute and/or chronic pain states in
which there is an inflammatory
component and as an analgesic in
acute migraine attack.
Phebra was granted marketing
approval for Naproxen Suspension
by the TGA in September this year,
replacing the previously available
Naprosyn oral suspension.The above article was sent to subscribers in Pharmacy Daily's issue from 20 Nov 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Nov 12
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.